background: Human embryonic stem cells (hESCs) are most commonly derived from the inner cell mass (ICM) of blastocyst stage embryos. While the majority of hESC lines originate from good-quality embryos donated after cryogenic storage, poor-quality embryos (PQEs) not suitable for clinical use have also been shown to generate hESC. This provides a newfound function for embryos that would otherwise be discarded following IVF or ICSI. Owing to their lack of clinical importance, however, data on the poorest embryos in a cohort go largely unreported in the literature. It is therefore of interest to better understand the availability of PQEs from IVF/ICSI cycles and to determine their ability to develop into blastocysts with good-quality ICMs for use in hESC derivation. In this study, we investigate the influence of patient parameters and embryo cohort on PQE incidence, blastocyst development, ICM quality and successful hESC derivation from donated PQEs. methods: PQEs from 736 patient cycles that did not meet our clinical criteria for transfer or cryopreservation were cultured until Day 6 of development and assessed for blastocyst formation and ICM quality. A subset of blastocysts with good-quality ICMs were then used for hESC derivation attempts. Anonymous patient data such as maternal age, embryo history and cohort parameters were then retrospectively compiled and analysed.
Introduction
During assisted reproductive technology (ART), controlled ovarian hyperstimulation is used to obtain a certain number of oocytes with the intent of creating a cohort of embryos for clinical use (Willis et al., 2011) . From this cohort, embryos with high implantation potential are selected to be either transferred to the patient or cryopreserved for use in future cycles (Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology, 2011). Alternatively, the embryos in a cohort that display abnormal development or have traits known to correlate with low implantation potential are typically discarded following cycle completion. Despite improvements in human embryo culture conditions and implantation rates, there still remains an inherent degree of embryonic loss during in vitro culture (Patrizio and Sakkas, 2009) . As a result, disparities in embryo quality are routinely observed within individual embryo cohorts and poor-quality embryos (PQEs) are a common and accepted by-product of most IVF/ICSI cycles (Racowsky, 2002) .
Despite their inferior quality, PQEs are proving to be an abundant and viable source for the derivation of human embryonic stem cells (hESCs). HESC lines that arise from PQEs exhibit the defining features of pluripotency and self-renewal and can maintain a stabile karyotype after extensive passaging (Raya et al., 2008; Venu et al., 2010) . Blastocysts originating from PQEs have recently been shown to generate hESC at a similar efficiency as those originating from good-quality embryos (Strom et al., 2010) . In addition, the majority of patients undergoing ART favour donation of their PQEs to hESC research rather than discarding them (Bjuresten and Hovatta, 2003; Hug, 2008; Jain and Missmer, 2008) . The use of PQEs for hESC derivation thus provides a newfound function for embryos that would previously have been discarded. Effective utilization of PQEs, however, requires additional insight into their availability during ART and a better understanding of their developmental competence for use in hESC generation.
Efficient derivation of hESC is dependent upon embryos developing into blastocysts that contain distinct inner cell mass (ICM) (Lerou et al., 2008) . Cleavage stage embryos with specific poor quality traits are known to have suboptimal development, decreased implantation potential and an increased incidence of chromosomal abnormalities (Lewin et al., 1994; Balakier and Cadesky, 1997; Jackson et al., 1998; Alikani et al., 2000; Marquez et al., 2000; Ebner et al., 2003 Ebner et al., , 2001 Hardarson et al., 2003 Hardarson et al., , 2001 Gianaroli et al., 2007; Magli et al., 2007) . Despite this, PQEs still have the potential to develop into blastocysts with good-quality ICMs, but may have compromised implantation potential (Della Ragione et al., 2007) . We have previously shown that PQEs are a heterogeneous population with a range of abnormal traits that can influence blastocyst development and hESC derivation (O' Leary et al., 2011) . Embryo morphology, however, is only one variable influencing successful IVF outcome. Patient-specific parameters such as maternal age and responsiveness to ovarian stimulation can also impact embryo development and competency (Broekmans et al., 2007; van Loendersloot et al., 2010) . In addition, cohort-specific parameters that portray sibling embryos as a group can provide additional prognostic value in predicting IVF success (Jun et al., 2008) . Cohort parameters such as the number of oocytes retrieved, fertilization rate and number of good-quality embryos available have been shown to be important predictors of IVF outcome (Cai et al., 2011; Banerjee et al., 2010) . These prognostic variables, however, have only proved valid in the clinical setting when the top-quality embryos in a cohort are utilized and successful pregnancy is an endpoint. It is unknown if patient and cohort parameters similarly influence the competence of embryos displaying abnormal characteristics to generate hESC.
Since PQEs are commonly encountered in both good and poor prognosis cycles, it can be hypothesized that their cycle of origin can influence their ability to develop into blastocysts capable of generating hESC. This study was implemented to determine if predictors of clinical outcome can also influence the developmental competence of the poorest embryos in a cohort. In doing so, we gained valuable insight into the incidence and origin of PQEs encountered during ART and determined which of such embryos are most competent at generating good-quality ICM and subsequent hESC lines.
Materials and Methods

Ethical approval
Institutional Review Board approval was obtained from the Ethical Committee, Ghent University Hospital (2009/281) and the Belgian Federal Ethical Committee on Embryo Research (ADV 022). All patients donating embryos signed informed research consents specific to hESC research prior to their IVF/ICSI cycle.
Study design
This study is a retrospective data analysis of ongoing PQE culture for hESC derivation research. For the hESC derivation portion of this study, only attempts involving fresh, good-quality ICM and standard derivation methodology were analysed.
Embryo source
At the time of this study, our centre primarily performed embryo transfer and cryopreservation on Day 2 or Day 3 of embryonic development (with the day of oocyte retrieval being Day 0). Embryos were thus classified as poor quality based on morphological assessment on Days 1, 2 and 3 of development. Embryos were classified as poor quality if they did not meet the IVF laboratory's cryopreservation criteria due to high fragmentation (≥25%) on Day 2 or Day 3 of development, multinucleated blastomeres on Day 2, delayed development (,5 blastomeres on Day 3 or a ≤1 blastomere increase from Day 2 to 3) and/or abnormal fertilization [0, 1 or ≥3 pronucleate (PN)] on Day 1. Embryos were included into the study on Day 3 of development if they contained at four blastomeres and had ≤50% fragmentation. Patients with at least one embryo meeting these criteria were included in the embryo cohort analysis. In addition, cycles utilizing donor oocytes were excluded from data analysis.
Embryo culture
Following inclusion into the study, Day 3 embryos were transferred to individual culture drops of Cook blastocyst medium (Cook Ireland Ltd., Limerick, Ireland) and cultured at 378C, 6% CO 2 and 5% O 2 until Day 6 of development. Embryo culture from the zygote stage to Day 3 was in Cook Cleavage medium (Cook Ireland Ltd) at 378C under atmospheric oxygen and 5% CO 2 . On Day 6, any blastocyst that developed was scored using the grading system taken from International community consensus standard for reporting derivation of hESC lines by Stephenson et al. (2007) . Under this scoring system, ICM grades A and B are reserved for large and distinct ICMs with grade A being more compact and B having larger, less compact cells. Grade C scoring is used for small ICMs, grade D for degenerating ICMs and grade E when no apparent ICM is visible. For this study, grades A and B were considered good-quality ICMs for potential use in hESC derivation.
HESC derivation
Details of the hESC lines generated and the derivation method were described previously (O'Leary et al., 2011) . Briefly, only Day 6 blastocysts with grades A and B ICMs were used for derivation purposes. Zonapellucida free blastocysts were seeded on a nearly confluent layer of mitomycin-C (Sigma)-inactivated CD1 mouse embryonic fibroblasts (MEFs) in a center well organ culture dish (Falcon 3037, VWR, Leuven, Belgium) covered in hESC culture medium consisting of Knockout Dulbecco's Modified Eagle Medium (Invitrogen, Gent, Belgium), 20% Knockout Serum Replacement (Invitrogen), 1% non-essential amino acids (Invitrogen), 0.1 mM L-glutamine (Invitrogen), 1% Penicillin/Streptomycin (Invitrogen), 0.1 mM beta-mercaptoethanol (Sigma) and 4 ng/ml basic fibroblast growth factor (Invitrogen) and incubated at 378C, 6% CO 2 and 5% O 2 . Any ICM organization/growth was mechanically dissected and moved to fresh MEFs 4 -7 days after initial culture and observed for hESC-like outgrowth. The resulting hESC outgrowths were then propagated until initial characterization was performed and then cryopreserved. Characterization of established lines have been reported previously (O'Leary et al., 2011) .
Data analysis
On the day of inclusion into the study, all relevant embryo and patient data were recorded and individual embryos were given anonymous identifiers for tracking during experimental culture. Cohort data were then collected retrospectively from the clinical embryology database. Means were compared using one-way analysis of variance (ANOVA) followed by pair-wise comparisons using Tukey's test where more than two groups were compared. Percentages were compared by contingency table analysis followed by x 2 or Fisher's exact tests where appropriate. P ≤ 0.05 were considered to be significant.
Results
Figure 1 traces the fate of all oocytes and embryos from the 736 patient cycles that donated embryos for use in this study. We found that just over half of the embryos produced in our center (53.2%) were used clinically for either embryo transfer or cryopreservation.
Of the 2762 2PN embryos that did not meet criteria for clinical use, 71.2% (1966/2762) contained at least 4 cells and had ,50% fragmentation on Day 3 of development and were included in the study. In contrast, only 39.3% (680 of 1728) of the non-2PN embryos available for use met the inclusion criteria for this study. Non-2PN and 2PN PQEs meeting our inclusion criteria did not differ significantly in Figure 1 The fate of all oocytes and embryos originating from the 736 patient cycles donating PQEs for this study.
Stem cells from poor-quality human embryos blastocyst development or ICM quality and were subsequently grouped together for overall PQE analysis. In total, a mean of 3.6 + 2.8 embryos were donated per cycle with 32.6% developing to the blastocyst stage. Overall, 0.5 blastocysts with good-quality ICM were produced per donating cycle, which is 13.9% of embryos included in the study or 42.6% of blastocysts produced. The influence of patient age and cycle outcome on the origin and development of PQEs is presented in Fig. 2 . There were no significant differences observed in the mean number of PQEs donated between cycles resulting in a positive pregnancy test or those that did not ( Fig. 2A) . Similarly, PQEs originated from all maternal age groups with equal frequency (Fig. 2B) . As a result, the PQE pool is reflective of the demographics of the donating cycles. In our clinic, for example, 39.4% (290 of 736) of the patients in this study were in the 30 -34 age group and they donated 40.4% (1069 of 2646) of embryos in the PQE pool. However, blastocyst development and ICM quality differed Figure 2 The incidence and development of PQEs as stratified by (A) cycle outcome and (B) maternal age. Pie charts represent the proportion from each group of the PQEs in the pool. Excepting the number of cycles, data in the tables are means + SD or proportions (%). Differences in proportions were tested by the x 2 test or Fishers exact test as appropriate.
significantly when stratified by cycle outcome and maternal age. PQEs originating from cycles that resulted in a positive pregnancy test had significantly better blastocyst development and produced more blastocysts with good-quality ICM when compared with cycles that did not result in pregnancy. HESC outgrowth efficiency was not influenced by the pregnancy outcome of the donating cycle. There was a significant decrease in blastocyst development and ICM quality in PQEs originating from patients at the age of 38 and above and no hESC outgrowths were observed. Next, we looked at the successive hurdles a PQE must overcome to in order to generate hESC. We compared cohort parameters for cycles that did or did not produce at least one blastocyst ( Table I ), cycles that produced at least one blastocyst with good versus only poor-quality ICM (Table II) and cycles in which good-quality ICM were plated and did or did not generate hESC (Table III) . From the 736 cycles donating PQEs, 300 (40.8%) did not produce a single blastocyst. These cycles significantly differed from cycles that produced at least one blastocyst in all 11 of the cohort parameters analysed. Of the 436 cycles that produced blastocysts, 198 (45.4%) did not produce a single good-quality ICM. In comparison to cycles that produced at least one good-quality ICM, cycles producing only poorquality ICM had significantly fewer embryos donated per cycle, blastocysts per cycle and 2PN embryos per cycle as well as having a lower percentage of blastocyst development per donated embryo. Of the 238 cycles with good-quality ICM, 136 blastocysts were used for hESC derivation purposes from 96 cycles. Initial hESC outgrowths were generated from 21 ICM explants originating from 18 cycles. The 78 cycles that did not produce hESC had a significantly higher maternal age, a lower percentage of mature oocytes, lower blastocyst development and fewer blastocysts with good-quality ICM when compared with the hESC producing cohorts.
We had a 15.4% hESC derivation efficiency using PQEs that developed into blastocysts with good-quality ICM. By looking only at the cohorts from which derivation attempts were made, we found an overall derivation efficiency of 4.2% per embryo donated. Of the 21 hESC outgrowths observed, 16 were propagated into fully characterized lines with normal karyotype (O'Leary et al., 2011) . Abnormally fertilized embryos generated hESC outgrowths at a similar efficiency as those with normal fertilization. However, two out of five hESC outgrowths originating from abnormally fertilized embryos had abnormal karyotypes at early passage. A 1PN blastocyst resulted in tetraploid hESC and a 3PN blastocyst resulted in a triploid line that could not be propagated indefinitely (O'Leary et al., 2011) . The remaining hESC outgrowths (n ¼ 3) underwent several passages and had initial characterization but were not propagated further into fully characterized lines.
Discussion
The efficient utilization of PQEs for hESC derivation requires a better understanding of their incidence and developmental competence during ART. This study provides crucial data on the extent of embryonic loss during IVF/ICSI and demonstrates that PQEs are an abundant resource with applicable developmental competence for use in hESC derivation. We found that the ability of PQEs to develop into blastocysts having good-quality ICM and the competency for those ICM to generate hESC were influenced by prognostic variables reflective of their donating cycle. Since good-quality ICM were not equal in their ability to generate hESC, understanding the patient and cohort parameters of the embryos comprising the PQE pool can help predict hESC derivation efficiency and aid in establishing experimental groups with equal developmental competence. In this study, we have demonstrated that PQEs originate from both good and poor prognosis cycles and this contributes to the mixed developmental competence of the PQE pool. We found that the number of PQEs donated per cycle did not significantly differ when stratified by maternal age or by the ultimate indicator of cycle quality, pregnancy outcome. The PQEs that originated from older patients (.37 year) or from cycles that did not result in pregnancy, however, had significantly diminished blastocyst development and ICM quality. Maternal age was also shown to further influence the ability of good-quality ICMs to generate hESC. This report is the first to suggest that the age-related decline in human fertility also negatively affects the successful derivation of hESC. Since variations in maternal age and cycle prognosis also underlie the developmental competence of goodquality embryos, these parameters should be considered in all hESC derivation experiments regardless of embryo source (Broekmans et al., 2007) .
Since embryos with poor-quality traits are rarely used for clinical purposes, information on their developmental competence is limited. We have determined that, similar to good-quality embryos, the developmental potential of PQEs is directly correlated to the overall developmental potential of the cohort from which they originate (Jun et al., 2008) . In this study, 40.8% of donating cycles had no blastocyst development from their PQEs and these cycles had a significantly lower pregnancy rate than those cohorts that produced blastocysts. Commonly used indicators of cycle quality such as the number of oocytes retrieved, number of mature oocytes, fertilization rate, cohort size and number of embryos cryopreserved were all significantly reduced in the non-blastocyst producing cohorts when compared with those producing blastocysts. Alternatively, hESC generating cohorts produced the most blastocysts, had the highest percentage of goodquality ICM and had the highest pregnancy rate, indicating an overall increase in cohort health. In clinical ART, there is an inherent risk that patients scheduled for a blastocyst transfer will not have any blastocyst development (Thum et al., 2010) . Since PQE blastocyst development reflects overall cohort development, incorporation of PQE tracking could provide clinical insight and additional criteria for selecting which patients would and would not benefit from blastocyst stage transfer (Guerif et al., 2011) .
Only 33.3% of oocytes retrieved and 53.2% of 2PN embryos created met our clinical standards for transfer and cryopreservation. This high degree of embryonic loss is not unique to our setting as two previous studies investigating the biological inefficiency of ART found 31.2 and 38.4% of oocytes retrieved resulted in clinically usable embryos (Meniru and Craft, 1997; Patrizio and Sakkas, 2009 ). Additional dialogue regarding the incidence of PQEs during ART and the criteria used for designating PQEs is needed to assess inter-laboratory variations in PQE availability. In our center, a mean of 3.6 PQEs donated per patient indicates a substantial number of embryos are potentially available for embryo and hESC-related research following informed consent.
It did not escape our attention that a large proportion of embryos deemed to be of poor quality were actually competent for blastocyst development. Although similarly high blastocyst development has been reported for PQEs (Hardy et al., 1989; Shoukir et al., 1998) , it cannot be ruled out that a percentage of these embryos could have resulted in pregnancy if used clinically. In our centre, embryos with abnormal fertilization, severe fragmentation, multinucleated blastomeres and those with delayed development comprise our PQE pool. Embryos with these traits are excluded from clinical use as they have been shown to negatively correlate to implantation potential and are thought to indicate an increased risk of chromosomal errors (Balakier and Cadesky, 1997; Ziebe et al., 1997; Racowsky et al., 2003; Van Royen et al., 2003 , 1999 Stone et al., 2005; Scott et al., 2007) . In addition, certain types of PQEs have a higher susceptibility to cryopreservation damage that could further diminish implantation potential (Solé et al., 2011) . Although blastocyst development is an indication of further developmental competence, it remains unclear if blastocysts arising from PQEs are developmentally inferior to those arising from good-quality embryos. It should be noted that the blastocysts with good-quality ICM used in this study did not need to have good-quality trophectoderm or blastocoel expansion that would be required for clinical use. Based on this study, we are now re-assessing our cryopreservation criteria and may incorporate blastocyst cryopreservation in coordination with sequential scoring to maximize embryo use for the patients. Until innovations in selecting viable embryos for clinical use become available, morphology-based estimation of embryo competence will continue and PQEs will remain an unavoidable consequence of ART. It should also be noted that blastocyst development is not always a strict indicator of further developmental competence. Embryos with signs of 3PN fertilization for example, are capable of developing into blastocysts, but if implanted result in negative outcomes such as spontaneous abortions, congenital abnormalities and occasional live births followed by early postnatal death (Rosenbusch, 2008) . On the other hand, comparative evaluation of hESC lines generated from 0, 1 and 3PN embryos has revealed these discarded embryos can result in hESC with normal characteristics and stable karyotype (Huan et al., 2010) . Our results indicate non-2PN embryos that contain at least four blastomeres and have ,50% fragmentation on Day 3 are as competent as 2PN PQEs to develop to blastocysts with hESC comptent ICM. Since non-2PN embryos are very rarely used clinically, they can serve as a steady source for hESC derivation regardless of cryopreservation criteria.
The reported efficiency of hESC derivation from PQEs ranges from. 4.1 to 25% Mitalipova et al., 2003; Alikani and Munne, 2005; Chen et al., 2005; Findikli et al., 2005; Genbacev et al., 2005; Lysdahl et al., 2006; Zhang et al., 2006; Lerou et al., 2008; Raya et al., 2008; Cortes et al., 2009; Liu et al., 2009; Candan and Kahraman, 2010; Harkness et al., 2010; Skottman, 2010; Venu et al., 2010) . Our efficiency of 15.4% is within this range but effective comparison between laboratories is difficult due to inconsistent reporting of embryo use and blastocyst quality as well as variations in derivation methodology (Cortes et al., 2006) . Although hESC lines have been derived from poor-quality ICM, we chose to use only good-quality ICM in this study to allow for comparative analysis. By using only good-quality ICM, we were able to show that ICM quality alone is an incomplete predictor of hESC derivation. A goodquality ICM from a 38-year-old patient, for example, does not have the same hESC competence as a good-quality ICM from a 30-year-old patient. This study highlights the importance of incorporating embryological data in hESC derivation reporting. Different criteria for identifying PQEs between ART laboratories and differences in patient demographics could account for PQE pools with unequal developmental competence and could explain the differences in reported hESC derivation efficiencies. Importantly, comparative results claiming to improve hESC derivation efficiency through optimized culture and techniques need to account for the underlying embryological influences that could bias results.
Since the incidence of our PQEs, their blastocyst development and our hESC derivation efficiency are all similar to those reported in previous studies, it is possible to use our data to estimate the potential of PQEs in hESC derivation research. In the USA alone, 90 310 fresh IVF/ICSI cycles were reported in 2009, the last year in which data are available. Hypothetically, 325 116 embryos from these cycles (3.6 embryos per cycle) would be excluded from clinical use but still have at least 4 cells and ,50% fragmentation on Day 3 of development. Of these, 45 191 blastocysts with good-quality ICM (13.9%) could be produced, and if used for hESC derivation, 6959 novel lines could be generated (15.4% derivation efficiency). While these estimates are entirely theoretical, they demonstrate PQEs are an abundant resource and their efficient utilization could significantly advance hESC derivation research.
